uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation
Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Genetics and Pathology.
Show others and affiliations
2012 (English)In: Journal of Cellular and Molecular Medicine (Print), ISSN 1582-1838, Vol. 16, no 7, 1474-1484 p.Article in journal (Refereed) Published
Abstract [en]

Mucin glycoproteins are major secreted or membrane-bound molecules that, in cancer, show modifications in both the mucin proteins expression and in the O-glycosylation profile, generating some of the most relevant tumour markers in clinical use for decades. Thus far, the identification of these biomarkers has been based on the detection of either the protein or the O-glycan modifications. We therefore aimed to identify the combined mucin and O-glycan features, i.e. specific glycoforms, in an attempt to increase specificity of these cancer biomarkers. Using in situ proximity ligation assays (PLA) based on existing monoclonal antibodies directed to MUC1, MUC2, MUC5AC and MUC6 mucins and to cancer-associated carbohydrate antigens Tn, Sialyl-Tn (STn), T, Sialyl-Lea (SLea) and Sialyl-Lex (SLex) we screened a series of 28 mucinous adenocarcinomas from different locations (stomach, ampulla of Vater, colon, lung, breast and ovary) to detect specific mucin glycoforms. We detected Tn/STn/SLea/SLex-MUC1 and STn/SLea/SLex-MUC2 glycoforms in ≥50% of the cases, with a variable distribution among organs. Some new glycoforms – T/SLea-MUC2, STn/T/SLea/SLex-MUC5AC and STn/T/SLea/SLex-MUC6 – were identified for the first time in the present study in a variable percentage of cases from different organs. In conclusion, application of the PLA technique allowed sensitive detection of specific aberrant mucin glycoforms in cancer, increasing specificity to the use of antibodies either to the mucin protein backbone or the O-glycan haptens alone.

Place, publisher, year, edition, pages
2012. Vol. 16, no 7, 1474-1484 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-175474DOI: 10.1111/j.1582-4934.2011.01436.xISI: 000305791600012PubMedID: 21883895OAI: oai:DiVA.org:uu-175474DiVA: diva2:531639
Available from: 2012-06-07 Created: 2012-06-07 Last updated: 2012-07-19Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Söderberg, Ola
By organisation
Science for Life Laboratory, SciLifeLabDepartment of Genetics and PathologyMolecular tools
In the same journal
Journal of Cellular and Molecular Medicine (Print)
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 259 hits
ReferencesLink to record
Permanent link

Direct link